Results 41 to 50 of about 12,515 (211)

Promotion of Autophagy and Apoptosis in Colorectal Cancer Exposed to Imatinib and Thymoquinone

Journal of Biochemical and Molecular Toxicology, Volume 39, Issue 4, April 2025.
The combination of IM and TQ induced autophagy in HCT116 cell line which in turn enhanced apoptosis. The combination inhibited colonies formation as well as the increments of various apoptotic markers. AMPK, when senses the rising autophagy, it will always activate apoptosis in a stress‐defense response.
Dalia El‐Khouly, Nadia A. Thabet, Mohamed Sayed‐Ahmed, Mervat M. Omran   +3 more
wiley   +1 more source

Hepatic metastasis with heterologous rhabdomyoblastic differentiation in a patient with gastrointestinal stromal tumor treated with imatinib

Indian Journal of Pathology and Microbiology, 2013
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the intestinal tract. In patients with locally advanced and/or metastatic GIST, the introduction of tyrosine kinase inhibitor, imatinib mesylate, has transformed the ...
Mukul Vij, Susama Patra, Mohamed Rela
doaj   +1 more source

STAT3 Signaling Pathway in Health and Disease

MedComm, Volume 6, Issue 4, April 2025.
An image depicting the role of STAT3 in various human diseases ABSTRACT Signal transducer and activator of transcription 3 (STAT3) is a critical transcription factor involved in multiple physiological and pathological processes. While STAT3 plays an essential role in homeostasis, its persistent activation has been implicated in the pathogenesis of ...
Md Abdus Samad, Iftikhar Ahmad, Aakifah Hasan, Mohammad Hassan Alhashmi, Arusha Ayub, Fahad A. Al‐Abbasi, Ajoy Kumer, Shams Tabrez   +7 more
wiley   +1 more source

SUCCINATE DEHYDROGENASE SUBUNIT B DEFICIENT PEDIATRIC GIST

Hematology, Transfusion and Cell Therapy, 2022
Case report Gastrointestinal stromal tumors (GISTs) occur exceedingly rare in children and adolescents. Eighty five percent of pediatric GISTs and 15 % of adult GISTs lack oncogenic mutations in KIT and PDGFRA.
Melek Yaman Ortakoylu, Sonay Incesoy Ozdemir, Handan Dincaslan, Nurdan Tacyildiz, Isınsu Kuzu, Emel Cabi Unal   +5 more
doaj  

The Adverse Impact of Tyrosine Kinase Inhibitors on Wound Healing and Repair

International Wound Journal, Volume 22, Issue 4, April 2025.
ABSTRACT Tyrosine kinase inhibitors (TKIs) can treat various cancers, primarily through their antiangiogenic effects. However, as angiogenesis is crucial for successful wound healing, TKIs may adversely impact wound repair. This review analysed all 63 FDA‐approved TKIs and identified evidence for wound healing and repair implications in 24 agents.
William J. Nahm, Vincent Falanga
wiley   +1 more source

Pulmonary Hypertension: Molecular Mechanisms and Clinical Studies

MedComm, Volume 6, Issue 3, March 2025.
The figure highlights the interplay of genetic and epigenetic mechanisms in pulmonary hypertension (PH) and their implications for therapeutic strategies. The genetic mechanism section features key genes implicated in PH pathogenesis. The epigenetic mechanism encompasses DNA methylation, RNA methylation, noncoding RNAs (miRNA, lncRNA), and histone ...
Joseph Adu‐Amankwaah, Qiang You, Xiaoer Liu, Jiayi Jiang, Dongqi Yang, Kuntao Liu, Jinxiang Yuan, Yanfang Wang, Qinghua Hu, Rubin Tan   +9 more
wiley   +1 more source

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink   +10 more
wiley   +1 more source

Imatinib resistance: diagnostic and therapeutic choices

Clinical Management Issues, 2015
We report a case of a 42-year-old woman with t(9;22) positive chronic myeloid leukemia (CML) who developed a sub-optimal response to therapy with imatinib mesylate due to M351T mutation and low plasma level of imatinib. Dose increase of imatinib resulted
Marianna De Muro, Odoardo Maria Olimpieri, Rosa Greco, Lidia Altomare   +3 more
doaj   +1 more source

Single‐center off‐label benralizumab use for refractory hypereosinophilic syndrome demonstrates satisfactory safety and efficacy

eJHaem, Volume 6, Issue 1, February 2025.
Abstract Introduction Benralizumab is an interleukin 5‐receptor‐blocking drug registered for the treatment of eosinophilic asthma. It has proven efficient and safe in a small phase‐II trial in hypereosinophilic syndrome and is currently being investigated in a larger, randomized phase‐III trial.
Yvonne Veltman, Anna M. Aalbers, Maud A. W. Hermans, Pim G. N. J. Mutsaers   +3 more
wiley   +1 more source

Complete response to imatinib treatment in jejunal leiomyosarcoma subsequently developing gastrointestinal stromal tumor and desmoid tumor

American Journal of Experimental and Clinical Research, 2014
A unique case of a 50-year-old Japanese male with jejunal leiomyosarcoma (LMS) who subsequently developed gastrointestinal stromal tumor (GIST) and desmoid tumor (DT) during five years and six months after the initial surgery is reported. The patient was
Yuji Kurihara, Yoshio Sakai, Takeshi Tomita   +2 more
doaj